SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is attracting intense investor attention following a significant regulatory approval in Japan and growing anticipation for upcoming U.S. clinical trial milestones. The community is actively discussing the stock's long-term potential as a transformative oncology platform, with many members highlighting strong institutional accumulation and upward price target revisions as signs that the company is currently undervalued.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging as investors hedge against Middle Eastern geopolitical instability and the resulting threat to global energy supplies, particularly in the European natural gas sector. The stock has become a focal point for the trading community, which is actively discussing its low float, high cost-to-borrow fees, and the potential for a significant short squeeze.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors grapple with extreme price volatility and a massive valuation premium relative to the fund's underlying asset value, fueled by intense community speculation surrounding potential high-profile IPOs. Discussion is sharply divided between those betting on a continued short squeeze or future entry into private tech giants and critics who warn of an inevitable correction given the fund's limited float and disconnected price structure.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving a major analyst upgrade from Rothschild & Co that lifted its price target to $40, fueling community optimism about the company's best-in-class potential in the hidradenitis suppurativa market. Investors are actively discussing the upcoming 40-week long-term data readout at the AAD conference, with many betting that sustained positive clinical results will validate the firm's pipeline and reinvigorate long-standing buyout speculation.

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Zymeworks Inc

Zymeworks is gaining significant attention after receiving FDA Fast Track Designation for its antibody-drug conjugate ZW191, a key development for treating advanced platinum-resistant ovarian cancer. The community is buzzing over this regulatory milestone, with active discussions focused on the drug's potential as a best-in-class therapy and the company's broader positioning as a high-potential candidate for M&A activity within the oncology sector.

Archer-Daniels-Midland Co. engages in the production of oilseeds, corn, wheat, cocoa, and other agricultural commodities. It operates through the following segments: Ag Services and Oilseeds, Carbohydrate Solutions, Nutrition, and Other. The Ag Services and Oilseeds segment includes activities related to the origination, merchandising, transportation, and storage of agricultural raw materials, and the crushing and further processing of oilseeds such as soybeans and soft seeds cottonseed, sunflower seed, canola, rapeseed, and flaxseed into vegetable oils and protein meals. The Carbohydrate Solutions segment consists of corn and wheat wet and dry milling and other activities. The Nutrition segment serves various end markets including food, beverages, nutritional supplements, and feed and premix for livestock, aquaculture, and pet food. The Other segment refers to the company's remaining operations. The company was founded in 1902 and is headquartered in Chicago, IL.

Archer Daniels Midland Co.

Archer Daniels Midland is experiencing heightened volatility ahead of its upcoming earnings report as investors weigh mixed Q3 projections against ongoing concerns regarding segment performance and biofuel policy uncertainty. The community remains deeply divided, with some traders eyeing value-driven entry points near current levels, while others highlight skepticism regarding leadership and recent accounting investigations as major hurdles for the stock.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as the community highlights the platform's role in the real-world asset (RWA) sector through partnerships with major financial institutions like BlackRock and Franklin Templeton. Discussions are focused on long-term growth potential and institutional adoption, though some investors are expressing frustration over price stagnation and upcoming token unlocks.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is facing significant selling pressure as investors weigh robust long-term AI demand against mounting macro headwinds, including geopolitical tensions in the Middle East and a broader rotation out of high-valuation tech stocks. The community remains deeply divided, with many traders debating whether the current pullback offers a strategic entry point for long-term growth or signals a deeper correction amidst semiconductor supply chain risks and shifting market sentiment.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending due to the company's mixed fourth-quarter earnings report, where a revenue beat and a new seventy-five million dollar share buyback program were overshadowed by continued manufacturing yield constraints and delays in smartphone battery qualification. The community is sharply divided, with bulls pointing to the company's strong cash position and recent defense contract wins as validation, while bears are aggressively highlighting persistent production bottlenecks and the absence of high-volume commercial purchase orders.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy Co. is experiencing intense volatility and heavy trading volume as retail traders speculate on the company's Arctic oil exploration prospects following its recent NASDAQ debut. While bullish community members are highlighting the potential of the Jameson Land Basin and high-profile strategic advisors, others are actively debating the sustainability of the price action, with some warning of a potential short squeeze or volatility driven by the company's small float.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

At NIBA&#39;s 152nd Investment Conference in Fort Lauderdale on March 12, 2026, Genvor, Inc. (OTCQB: $GNVR) CEO Chad Pawlak, Sr. explained where peptides fit in the evolution of agricultural biologicals -- and why the category has finally caught up to the promise. 
 
Genvor Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. 
 
Agricultural biologicals have evolved across three generations: from plant-based botanicals, to fermented microbial products, to today&#39;s engineered peptides, proteins, and enzymes. Pawlak explained what makes the third generation different: 
 
&quot;What&#39;s important here at Genvor is not that we&#39;re a product company. It&#39;s that we have a machine learning AI model that is based on actual data. What not everybody has is the data behind it... We can sequence peptides in a way that nobody else can do.&quot; 
- First generation: botanicals (seaweed biostimulants, chrysanthemum-derived insecticides) 
- Second generation: fermented biological products (bacillus, trichoderma, rhizobium) 
- Third generation: peptides, proteins, and enzymes -- synthetic-chemistry efficacy with biological upside 
- The prior generations&#39; problem: inconsistent efficacy, limiting adoption by growers and investors 
 
Watch the clip: https://youtube.com/shorts/emFqFPYPLo4 
 
Read the press release: https://finance.yahoo.com/news/genvor-inc-presenting-nibas-152nd-130000396.html 
 
Genvor is led by CEO Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://www.genvor.com. For investor inquiries, contact investors@genvor.com. 
 
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. 
 
$GNVR $AGTECH $AGBIO $AI $BIOTECH $OTC $SMALLCAP

David Shapiro

Brogley Panzarella

Ball Terjova

Ria Thiel

Allie Walker

Bana Daerhova

Refugio Bergstrom

top moon

Mangine Mckelvy

Craig Salinas

Ariana Storck

The team specializes in AI-accelerated peptide design for crop protection, leveraging extensive expertise in computational biology, agricultural pathogen control, and regulatory navigation to deliver sustainable solutions to growers worldwide. The Genvor Inc. executive leadership regularly updates investors with company news. Please fill out this form to receive the latest information.

B2idigital

Genvor Incorporated on b2i Digital

YouTube

At NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, 2026, Genvor, Inc. - Clip 1

CEO Chad Pawlak to deliver corporate update on AI-accelerated peptide platform and strategic growth initiatives WOODLAND, CA / ACCESS Newswire / March 5, 2026 /Genvor, Inc. (OTCQB:GNVR) ("Genvor" or the "Company") is pleased to announce that Chief ...

Yahoo Finance

Genvor, Inc. Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026

Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI-accelerated peptide discovery to deliver high-performance solutions across agriculture and human health & wellness. The company's proprietary BioCypher algorithm designs peptides that enhance crop performance, reduce chemical inputs, and support human recovery, performance, and daily wellness.

Genvor

Genvor | Pioneering the Future of Plant Health and Human Wellness

b2i digital - connecting companies and investors through digital marketing, investor conferences, and direct introductions and meetings.

B2i Digital - Connecting companies and investors

StockTwits For Android 

GNVR_IR

StockTwits Web

Genvor Inc

C3.ai Inc

At NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, 2026, Genvor, Inc. (OTCQB: 

) CEO Chad Pawlak, Sr. explained where peptides fit in the evolution of agricultural biologicals -- and why the category has finally caught up to the promise. 
 
Genvor Inc. is a B2i Digital Featured Company. Learn more at 

. 
 
Agricultural biologicals have evolved across three generations: from plant-based botanicals, to fermented microbial products, to today's engineered peptides, proteins, and enzymes. Pawlak explained what makes the third generation different: 
 
"What's important here at Genvor is not that we're a product company. It's that we have a machine learning AI model that is based on actual data. What not everybody has is the data behind it... We can sequence peptides in a way that nobody else can do." 
- First generation: botanicals (seaweed biostimulants, chrysanthemum-derived insecticides) 
- Second generation: fermented biological products (bacillus, trichoderma, rhizobium) 
- Third generation: peptides, proteins, and enzymes -- synthetic-chemistry efficacy with biological upside 
- The prior generations' problem: inconsistent efficacy, limiting adoption by growers and investors 
 
Watch the clip: 

 
 
Genvor is led by CEO Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit 

. For investor inquiries, contact investors@genvor.com. 
 
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at 

. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. 
 


Applied Energetics, Inc.

NASDAQ Composite

SuperCom Ltd

Applied Dna Sciences Inc

Heidmar Maritime Holdings Corp. Common Stock

OS Therapies Inc

eXoZymes Inc.

Kolibri Global Energy Inc

Genvor Inc. is advancing agricultural biologicals through AI-driven peptide discovery, combining data science with decades of peptide research. The company’s approach highlights how third-generation biologicals may deliver more consistent performance for growers. 
 
Learn more about Genvor Inc. and its technology platform at 
https://b2idigital.com/genvor-incorporated

Genvor Inc. is advancing agricultural biologicals through AI-driven peptide discovery, combining data science with decades of peptide research. The company’s approach highlights how third-generation biologicals may deliver more consistent performance for growers. 
 
Learn more about Genvor Inc. and its technology platform at 
